ProJenX, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProJenX, Inc. - overview
Established
2021
Location
-, NY, US
Primary Industry
Biotechnology
About
Founded in 2021 and based in New York, US, ProJenX, Inc. operates as a clinical-stage biotechnology company that researches and develops therapies for ASL and other neurodegenerative diseases with Prosetin, a MAP4K inhibitor therapy. The company was co-founded by Arie Zask, Emily Lowry, Hynek Wichterle, and Brent Stockwell. As of 2023, the company is led by its CEO, Stan Abel.
In November 2023, ProJenX, Inc. raised USD 15 million in Series A funding led by Medical Excellence Capital. The company is developing novel, brain-penetrant therapies for the treatment of debilitating brain diseases, with an initial focus on ALS. The company's aims to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.
Current Investors
Medical Excellence Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.projenx.com/
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.